| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1084131550 |
| P356 | DOI | 10.1038/SREP43639 |
| P932 | PMC publication ID | 5337947 |
| P698 | PubMed publication ID | 28262728 |
| P2093 | author name string | Kun Ping Lu | |
| Ting-Fen Tsai | |||
| Min Zheng | |||
| Xiao Zhen Zhou | |||
| Xin-Hua Liao | |||
| Huijuan Xu | |||
| Arina Li Zhang | |||
| Champ Peng Chen | |||
| Dayun Yang | |||
| Hekun Liu | |||
| Mei-Qing Li | |||
| Qing-Song Chu | |||
| Wenxian Lu | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC | Q24291638 | ||
| A Pin1/mutant p53 axis promotes aggressiveness in breast cancer | Q24312083 | ||
| The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer | Q24317638 | ||
| Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. | Q24535558 | ||
| Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges | Q26744100 | ||
| Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins | Q26825421 | ||
| Structure-based design of novel human Pin1 inhibitors (I) | Q27657296 | ||
| All trans retinoic acid in acute promyelocytic leukemia | Q27824776 | ||
| Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia | Q44568308 | ||
| Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. | Q46656681 | ||
| Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G(0) arrest | Q47900743 | ||
| PIN1 gene overexpression and beta-catenin gene mutation/expression in hepatocellular carcinoma and their significance. | Q53335167 | ||
| Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia | Q54277096 | ||
| Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone. | Q55067472 | ||
| Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo | Q67896432 | ||
| Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer | Q74418877 | ||
| Targeted cancer therapies | Q84334032 | ||
| Intratumor molecular and phenotypic diversity in hepatocellular carcinoma | Q86613166 | ||
| The consensus coding sequences of human breast and colorectal cancers | Q27861035 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia | Q28291815 | ||
| Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer | Q28316780 | ||
| Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation | Q28586404 | ||
| Principles of cancer therapy: oncogene and non-oncogene addiction | Q29616779 | ||
| Intra-tumour heterogeneity: a looking glass for cancer? | Q29620149 | ||
| A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. | Q33368982 | ||
| Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. | Q33561131 | ||
| Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer | Q33838491 | ||
| Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes | Q34009230 | ||
| STI571: a paradigm of new agents for cancer therapeutics | Q34482385 | ||
| Pin1 inhibitors: Pitfalls, progress and cellular pharmacology | Q34782041 | ||
| Treatment of acute promyelocytic leukemia with ATRA and As2O3: a model of molecular target-based cancer therapy | Q35087216 | ||
| Prevalent overexpression of prolyl isomerase Pin1 in human cancers | Q35097986 | ||
| Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer | Q35587470 | ||
| Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment | Q36745391 | ||
| Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies | Q36750049 | ||
| Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity. | Q36771967 | ||
| Epidemiology of hepatocellular carcinoma: consider the population | Q36930514 | ||
| The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease | Q36945537 | ||
| Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression. | Q37257716 | ||
| Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation | Q37356550 | ||
| Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis | Q37485770 | ||
| Acute promyelocytic leukaemia: novel insights into the mechanisms of cure | Q37802188 | ||
| Modern approaches to treating acute promyelocytic leukemia | Q37827280 | ||
| Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning. | Q38176242 | ||
| PIN1 in hepatocellular carcinoma is associated with TP53 gene status | Q38411804 | ||
| The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target | Q38852028 | ||
| Expression and significance of Pin1, β-catenin and cyclin D1 in hepatocellular carcinoma | Q38967340 | ||
| Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis | Q40154756 | ||
| PIN1 expression contributes to hepatic carcinogenesis. | Q40255809 | ||
| PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma | Q40570047 | ||
| PIN1 genetic polymorphisms and the susceptibility of HBV-related hepatocellular carcinoma in a Guangxi population | Q40880199 | ||
| Pin1 is required for sustained B cell proliferation upon oncogenic activation of Myc | Q40996455 | ||
| Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. | Q43023367 | ||
| A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer | Q44522352 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 43639 | |
| P577 | publication date | 2017-03-06 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways | |
| P478 | volume | 7 |
| Q47319547 | A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways. |
| Q58793896 | Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells |
| Q90659229 | Death-Associated Protein Kinase 1 as a Promising Drug Target in Cancer and Alzheimer's Disease |
| Q88727424 | Enhanced Sampling of Interdomain Motion Using Map-Restrained Langevin Dynamics and NMR: Application to Pin1 |
| Q91650512 | Function of PIN1 in Cancer Development and Its Inhibitors as Cancer Therapeutics |
| Q50995283 | Generation of a cell-permeable cycloheptapeptidyl inhibitor against the peptidyl-prolyl isomerase Pin1. |
| Q92512121 | Inhibition of peptidyl-prolyl isomerase (PIN1) and BRAF signaling to target melanoma |
| Q33728138 | Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma |
| Q37739814 | MicroRNA-140-5p inhibits hepatocellular carcinoma by directly targeting the unique isomerase Pin1 to block multiple cancer-driving pathways |
| Q59808745 | PIN1 in Cell Cycle Control and Cancer |
| Q47246498 | Pin1 facilitates isoproterenol‑induced cardiac fibrosis and collagen deposition by promoting oxidative stress and activating the MEK1/2‑ERK1/2 signal transduction pathway in rats |
| Q54917620 | Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways. |
| Q90739424 | Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway |
| Q90484451 | Post-translational Modifications of the Peptidyl-Prolyl Isomerase Pin1 |
| Q89496643 | Predictive Value of Pin1 in Cervical Low-Grade Squamous Intraepithelial Lesions and Inhibition of Pin1 Exerts Potent Anticancer Activity against Human Cervical Cancer |
| Q89497633 | Targeting PIN1 as a Therapeutic Approach for Hepatocellular Carcinoma |
| Q92425757 | Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis |
| Q92191083 | Targeting Pin1 by All-Trans Retinoic Acid (ATRA) Overcomes Tamoxifen Resistance in Breast Cancer via Multifactorial Mechanisms |
| Q48141356 | Targeting Pin1 by inhibitor API-1 regulates microRNA biogenesis and suppresses hepatocellular carcinoma development |
Search more.